{"entity":{"id":"brprophet","kind":"drug","name":"brPROPHET","aka":["PROPHET","Burning Rock PROPHET","Patient-specific pROgnostic and Potential tHErapeutic marker Tracking"],"tldr":"Burning Rock's personalised blood test for leftover lung cancer after surgery, which tracks up to 50 of the tumour's own mutations.","summary":"PROPHET (Patient-specific pROgnostic and Potential tHErapeutic marker Tracking) was described by Burning Rock Biotech and Chinese surgical groups in Cancer Cell in 2023: deep sequencing of 50 patient-specific variants, a stated limit of detection of 0.004 per cent, and 760 plasma samples from 181 prospectively enrolled patients with early-stage non-small cell lung cancer. It detected tumour DNA before surgery in 45 per cent of patients, outperformed fixed-panel assays for prognosis, and gave a median lead time of 299 days to radiologically confirmed recurrence. Of the variants it tracked, 98.2 per cent were not canonical driver mutations.\n\nBurning Rock states in a press release of 25 August 2026 that its CanCatch Custom kit entered China's NMPA special review procedure for innovative medical devices; that is entry to review, not registration, and was not checked on the NMPA site.","status":"emerging","asOf":"2026-11-04","links":[{"label":"Chen et al., PROPHET in early-stage NSCLC (Cancer Cell 2023)","url":"https://doi.org/10.1016/j.ccell.2023.08.010"},{"label":"Burning Rock: CanCatch Custom kit enters NMPA innovative device review (25 August 2026)","url":"https://www.brbiotech.com/details.php?class_id=105107103&id=550"}],"tags":["test","mrd"],"related":["minerva-prime","geneplus-personalised-mrd"],"cancers":["nsclc"],"sections":[],"technologies":["mrd-testing","liquid-biopsy"],"targets":[],"drugs":[],"companies":["burning-rock"],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-chen-prophet-nsclc-cancer-cell-2023"],"journals":[],"dependsOn":[],"notes":["Stated limit of detection, in the abstract's words: \"a limit of detection of 0.004%\" (Chen et al., Cancer Cell 2023). The full text gives probit limits of 0.0036 per cent at 20 ng and 0.0018 per cent at 60 ng input, measured on a diluted cell line, which is 36 and 18 parts per million.","Variant choice favours high allele fraction; the paper describes tracking trunk mutations shared by most tumour cells. It does not report which clone remains."],"brand":"brPROPHET","modality":"Tumour-informed ctDNA minimal residual disease test (up to 50 variants, hybrid capture)","mechanism":"Whole-exome sequencing of tumour and white blood cells selects up to 50 patient-specific variants, which a personalised capture panel then reads deeply in plasma with molecular barcodes.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/brprophet/","neighbours":{"drug":[{"id":"geneplus-personalised-mrd","kind":"drug","name":"Geneplus personalised MRD assay","route":"/drugs/geneplus-personalised-mrd/"},{"id":"minerva-prime","kind":"drug","name":"MinerVa Prime","route":"/drugs/minerva-prime/"}],"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"company":[{"id":"burning-rock","kind":"company","name":"Burning Rock Biotech","route":"/companies/burning-rock/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}],"paper":[{"id":"paper-chen-prophet-nsclc-cancer-cell-2023","kind":"paper","name":"Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer","route":"/key-papers/paper-chen-prophet-nsclc-cancer-cell-2023/"}]}}